| Originator | Generic Name | Any Pharmacology Description | Any Indication | Any Indication Status |
|---|---|---|---|---|
| Adherex | sodium thiosulfate, Adherex | Unidentified pharmacological activity | Hearing
loss Chemotherapy-induced injury, general |
Phase
II Clinical Trial Phase II Clinical Trial |
| GenVec | ATOH gene ther, GenVec | Unidentified pharmacological activity | Hearing loss | Preclinical |
| Xigen | XG-102 | JNK inhibitor | Ischaemia,
cerebral Infarction, myocardial |
Phase
I Clinical Trial Phase I Clinical Trial |
| Sound Pharmaceuticals | SPI-5505 | Gene expression inhibitor | Hearing loss | Preclinical |
| Living Cell Technologies | NeurotrophinCell | Not applicable | Huntington`s
disease Hearing loss |
Preclinical Preclinical |
| Sound Pharmaceuticals | ebselen, Sound Pharmaceuticals | Glutathione peroxidase stimulant | Hearing
loss Tinnitus |
Phase
I Clinical Trial Phase I Clinical Trial |
| Sound Pharmaceuticals | SPI-3005 | Unidentified pharmacological activity | Chemotherapy-induced
injury, general Hearing loss |
Preclinical Preclinical |
| Sound Pharmaceuticals | SPI-128 | Gene expression inhibitor | Hearing loss | Preclinical |
| Xigen | AM-111 | JNK
inhibitor Apoptosis antagonist |
Hearing loss | Phase II Clinical Trial |
| Auris Medical | AM-101, Auris | NMDA antagonist | Tinnitus | Phase II Clinical Trial |
| Kinex | KX-2-377 | Src inhibitor | Unspecified | Preclinical |
| Merck & Co | hearing loss therapy, Merck | Gene expression inhibitor | Hearing loss | Preclinical |
| Molecular Therapeutics | MRX-1024 | Unidentified pharmacological activity | Chemotherapy-induced
mucositis Chemotherapy-induced injury, general Hearing loss |
Phase
II Clinical Trial Phase II Clinical Trial Phase II Clinical Trial |
| Auris Medical | AM-102 | Unidentified pharmacological activity | Tinnitus | Preclinical |
| Quark Biotech | AHLi-11 | p53 inhibitor | Hearing loss | Preclinical |
| EpiCept | lidocaine, EpiCept-4 | Sodium
channel antagonist Potassium channel antagonist Membrane integrity antagonist |
Tinnitus Vertigo |
Phase
II Clinical Trial Phase II Clinical Trial |
| Labopharm | betahistine, Labopharm | Histamine agonist | Meniere's disease | Phase II Clinical Trial |
| Ipsen | EGb-761 | Free radical scavenger | Cognitive
disorder, general Alzheimer`s disease Vertigo Tinnitus Peripheral vascular disease |
Phase
III Clinical Trial Phase III Clinical Trial Phase I Clinical Trial Phase I Clinical Trial Phase I Clinical Trial |